Novel TLR7 agonist stimulates activity of CIK/NK immunological effector cells to enhance antitumor cytotoxicity
Toll-like receptor (TLR) 7/8 agonists have been applied in combination with chemo-, radio- or immunotherapy for lymphoma, and used as topical drugs for the treatment of viral skin lesions and skin tumors. In the present study, the role of an adenine analog, 9-(4-carboxyphenyl)-8-hydroxy-2-(2-methoxy...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2018-04, Vol.15 (4), p.5105-5110 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5110 |
|---|---|
| container_issue | 4 |
| container_start_page | 5105 |
| container_title | Oncology letters |
| container_volume | 15 |
| creator | Gao, Dong Cai, Yongguang Chen, Yanyuan Li, Wang Wei, Chih-Chang Luo, Xiaoling Wang, Yuhuan |
| description | Toll-like receptor (TLR) 7/8 agonists have been applied in combination with chemo-, radio- or immunotherapy for lymphoma, and used as topical drugs for the treatment of viral skin lesions and skin tumors. In the present study, the role of an adenine analog, 9-(4-carboxyphenyl)-8-hydroxy-2-(2-methoxyethoxy)-adenine [termed Gao Dong (GD)], a novel TLR7 agonist, in the activation of cytokine-induced killer/natural killer (CIK/NK) cells was determined. The results of the present study indicated that GD was able to activate CIK/NK cells. The proportion of GD-induced CD3
CD56
CIK and CD3
CD56
NK cells was ~4% higher respectively compared with the control. Notably, combination therapy with CIK/NK cells stimulated by GD, markedly suppressed the proliferation of the chronic myelogenous leukemia K562 cell line. Following GD treatment, the cytotoxicity improved by ~25 and 21% when the effector/target ratio was 20:1 and 10:1, respectively. The results of the present study suggested a novel protocol for CIK/NK cell proliferation and revealed that GD may serve as a potent innate and adaptive immunomodulator in immunocyte culture. |
| doi_str_mv | 10.3892/ol.2018.7954 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5840738</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A535030843</galeid><sourcerecordid>A535030843</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-c3615b9b4e08c5f1d22dbd1dd87a2e9c6f3b60714f850d5c900f1e7e34b25c013</originalsourceid><addsrcrecordid>eNptkt1rFDEUxQdRbKl981kCgvjgbvM5k3kRyuJH6VJB6nPIZJLdlExunWQW9783Q-vaFZOHhNzfPeEcblW9JnjJZEsvICwpJnLZtII_q05J09IFwZI-P9wbflKdp3SHyxI1kbJ-WZ3QVghKuDit4AZ2NqDb9fcG6Q1EnzJK2Q9T0NkmpE32O5_3CBxaXV1f3FwjPwxThAAbb3RA1jlrMozI2BASyoBs3OpoLNIx-zwNc2mfIcMvb4rQq-qF0yHZ88fzrPrx-dPt6uti_e3L1epyvTC8bvLCsJqIru24xdIIR3pK-64nfS8bTW1rase6GjeEOylwL0yLsSO2sYx3VBhM2Fn18UH3fuoG2xsb86iDuh_9oMe9Au3VcSX6rdrATgnJccNkEXj_KDDCz8mmrAafZpM6WpiSKrELTkTJs6Bv_0HvYBpjsVcoijklJeu_1EYHq3x0UP41s6i6FExghiVnhVr-hyq7t4M3EK3z5f2o4d2Thq3VIW8ThCl7iOkY_PAAmhFSGq07hEGwmodJQZhdSTUPU8HfPA3wAP8ZHfYbderD8Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2020421214</pqid></control><display><type>article</type><title>Novel TLR7 agonist stimulates activity of CIK/NK immunological effector cells to enhance antitumor cytotoxicity</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Gao, Dong ; Cai, Yongguang ; Chen, Yanyuan ; Li, Wang ; Wei, Chih-Chang ; Luo, Xiaoling ; Wang, Yuhuan</creator><creatorcontrib>Gao, Dong ; Cai, Yongguang ; Chen, Yanyuan ; Li, Wang ; Wei, Chih-Chang ; Luo, Xiaoling ; Wang, Yuhuan</creatorcontrib><description>Toll-like receptor (TLR) 7/8 agonists have been applied in combination with chemo-, radio- or immunotherapy for lymphoma, and used as topical drugs for the treatment of viral skin lesions and skin tumors. In the present study, the role of an adenine analog, 9-(4-carboxyphenyl)-8-hydroxy-2-(2-methoxyethoxy)-adenine [termed Gao Dong (GD)], a novel TLR7 agonist, in the activation of cytokine-induced killer/natural killer (CIK/NK) cells was determined. The results of the present study indicated that GD was able to activate CIK/NK cells. The proportion of GD-induced CD3
CD56
CIK and CD3
CD56
NK cells was ~4% higher respectively compared with the control. Notably, combination therapy with CIK/NK cells stimulated by GD, markedly suppressed the proliferation of the chronic myelogenous leukemia K562 cell line. Following GD treatment, the cytotoxicity improved by ~25 and 21% when the effector/target ratio was 20:1 and 10:1, respectively. The results of the present study suggested a novel protocol for CIK/NK cell proliferation and revealed that GD may serve as a potent innate and adaptive immunomodulator in immunocyte culture.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2018.7954</identifier><identifier>PMID: 29552145</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Antigens ; Cancer ; Care and treatment ; Cell culture ; Chemotherapy ; Cytokines ; Cytotoxicity ; Health aspects ; Immunology ; Immunotherapy ; Ligands ; Lymphocytes ; Lymphoma ; Methods ; Oncology, Experimental ; Patient outcomes ; Pharmaceutical industry ; T cell receptors ; Toll-like receptors</subject><ispartof>Oncology letters, 2018-04, Vol.15 (4), p.5105-5110</ispartof><rights>COPYRIGHT 2018 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2018</rights><rights>Copyright © 2018, Spandidos Publications 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c467t-c3615b9b4e08c5f1d22dbd1dd87a2e9c6f3b60714f850d5c900f1e7e34b25c013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840738/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840738/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,725,778,782,883,27911,27912,53778,53780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29552145$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gao, Dong</creatorcontrib><creatorcontrib>Cai, Yongguang</creatorcontrib><creatorcontrib>Chen, Yanyuan</creatorcontrib><creatorcontrib>Li, Wang</creatorcontrib><creatorcontrib>Wei, Chih-Chang</creatorcontrib><creatorcontrib>Luo, Xiaoling</creatorcontrib><creatorcontrib>Wang, Yuhuan</creatorcontrib><title>Novel TLR7 agonist stimulates activity of CIK/NK immunological effector cells to enhance antitumor cytotoxicity</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Toll-like receptor (TLR) 7/8 agonists have been applied in combination with chemo-, radio- or immunotherapy for lymphoma, and used as topical drugs for the treatment of viral skin lesions and skin tumors. In the present study, the role of an adenine analog, 9-(4-carboxyphenyl)-8-hydroxy-2-(2-methoxyethoxy)-adenine [termed Gao Dong (GD)], a novel TLR7 agonist, in the activation of cytokine-induced killer/natural killer (CIK/NK) cells was determined. The results of the present study indicated that GD was able to activate CIK/NK cells. The proportion of GD-induced CD3
CD56
CIK and CD3
CD56
NK cells was ~4% higher respectively compared with the control. Notably, combination therapy with CIK/NK cells stimulated by GD, markedly suppressed the proliferation of the chronic myelogenous leukemia K562 cell line. Following GD treatment, the cytotoxicity improved by ~25 and 21% when the effector/target ratio was 20:1 and 10:1, respectively. The results of the present study suggested a novel protocol for CIK/NK cell proliferation and revealed that GD may serve as a potent innate and adaptive immunomodulator in immunocyte culture.</description><subject>Antigens</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Cell culture</subject><subject>Chemotherapy</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Health aspects</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Lymphoma</subject><subject>Methods</subject><subject>Oncology, Experimental</subject><subject>Patient outcomes</subject><subject>Pharmaceutical industry</subject><subject>T cell receptors</subject><subject>Toll-like receptors</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkt1rFDEUxQdRbKl981kCgvjgbvM5k3kRyuJH6VJB6nPIZJLdlExunWQW9783Q-vaFZOHhNzfPeEcblW9JnjJZEsvICwpJnLZtII_q05J09IFwZI-P9wbflKdp3SHyxI1kbJ-WZ3QVghKuDit4AZ2NqDb9fcG6Q1EnzJK2Q9T0NkmpE32O5_3CBxaXV1f3FwjPwxThAAbb3RA1jlrMozI2BASyoBs3OpoLNIx-zwNc2mfIcMvb4rQq-qF0yHZ88fzrPrx-dPt6uti_e3L1epyvTC8bvLCsJqIru24xdIIR3pK-64nfS8bTW1rase6GjeEOylwL0yLsSO2sYx3VBhM2Fn18UH3fuoG2xsb86iDuh_9oMe9Au3VcSX6rdrATgnJccNkEXj_KDDCz8mmrAafZpM6WpiSKrELTkTJs6Bv_0HvYBpjsVcoijklJeu_1EYHq3x0UP41s6i6FExghiVnhVr-hyq7t4M3EK3z5f2o4d2Thq3VIW8ThCl7iOkY_PAAmhFSGq07hEGwmodJQZhdSTUPU8HfPA3wAP8ZHfYbderD8Q</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Gao, Dong</creator><creator>Cai, Yongguang</creator><creator>Chen, Yanyuan</creator><creator>Li, Wang</creator><creator>Wei, Chih-Chang</creator><creator>Luo, Xiaoling</creator><creator>Wang, Yuhuan</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180401</creationdate><title>Novel TLR7 agonist stimulates activity of CIK/NK immunological effector cells to enhance antitumor cytotoxicity</title><author>Gao, Dong ; Cai, Yongguang ; Chen, Yanyuan ; Li, Wang ; Wei, Chih-Chang ; Luo, Xiaoling ; Wang, Yuhuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-c3615b9b4e08c5f1d22dbd1dd87a2e9c6f3b60714f850d5c900f1e7e34b25c013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antigens</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Cell culture</topic><topic>Chemotherapy</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Health aspects</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Lymphoma</topic><topic>Methods</topic><topic>Oncology, Experimental</topic><topic>Patient outcomes</topic><topic>Pharmaceutical industry</topic><topic>T cell receptors</topic><topic>Toll-like receptors</topic><toplevel>online_resources</toplevel><creatorcontrib>Gao, Dong</creatorcontrib><creatorcontrib>Cai, Yongguang</creatorcontrib><creatorcontrib>Chen, Yanyuan</creatorcontrib><creatorcontrib>Li, Wang</creatorcontrib><creatorcontrib>Wei, Chih-Chang</creatorcontrib><creatorcontrib>Luo, Xiaoling</creatorcontrib><creatorcontrib>Wang, Yuhuan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gao, Dong</au><au>Cai, Yongguang</au><au>Chen, Yanyuan</au><au>Li, Wang</au><au>Wei, Chih-Chang</au><au>Luo, Xiaoling</au><au>Wang, Yuhuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel TLR7 agonist stimulates activity of CIK/NK immunological effector cells to enhance antitumor cytotoxicity</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>15</volume><issue>4</issue><spage>5105</spage><epage>5110</epage><pages>5105-5110</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Toll-like receptor (TLR) 7/8 agonists have been applied in combination with chemo-, radio- or immunotherapy for lymphoma, and used as topical drugs for the treatment of viral skin lesions and skin tumors. In the present study, the role of an adenine analog, 9-(4-carboxyphenyl)-8-hydroxy-2-(2-methoxyethoxy)-adenine [termed Gao Dong (GD)], a novel TLR7 agonist, in the activation of cytokine-induced killer/natural killer (CIK/NK) cells was determined. The results of the present study indicated that GD was able to activate CIK/NK cells. The proportion of GD-induced CD3
CD56
CIK and CD3
CD56
NK cells was ~4% higher respectively compared with the control. Notably, combination therapy with CIK/NK cells stimulated by GD, markedly suppressed the proliferation of the chronic myelogenous leukemia K562 cell line. Following GD treatment, the cytotoxicity improved by ~25 and 21% when the effector/target ratio was 20:1 and 10:1, respectively. The results of the present study suggested a novel protocol for CIK/NK cell proliferation and revealed that GD may serve as a potent innate and adaptive immunomodulator in immunocyte culture.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>29552145</pmid><doi>10.3892/ol.2018.7954</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2018-04, Vol.15 (4), p.5105-5110 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5840738 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Antigens Cancer Care and treatment Cell culture Chemotherapy Cytokines Cytotoxicity Health aspects Immunology Immunotherapy Ligands Lymphocytes Lymphoma Methods Oncology, Experimental Patient outcomes Pharmaceutical industry T cell receptors Toll-like receptors |
| title | Novel TLR7 agonist stimulates activity of CIK/NK immunological effector cells to enhance antitumor cytotoxicity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T00%3A33%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20TLR7%20agonist%20stimulates%20activity%20of%20CIK/NK%20immunological%20effector%20cells%20to%20enhance%20antitumor%20cytotoxicity&rft.jtitle=Oncology%20letters&rft.au=Gao,%20Dong&rft.date=2018-04-01&rft.volume=15&rft.issue=4&rft.spage=5105&rft.epage=5110&rft.pages=5105-5110&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2018.7954&rft_dat=%3Cgale_pubme%3EA535030843%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2020421214&rft_id=info:pmid/29552145&rft_galeid=A535030843&rfr_iscdi=true |